The Price of Making Costs Visible

The Promise: When Price Stops Being a Mystery

What happens when a system built on hidden prices suddenly makes those prices visible? At first, it sounds like a cleanup project, the kind of obvious improvement everyone should welcome. If people can see the cost of care before they receive it, they can make better choices. If pharmacies are paid closer to acquisition cost plus a transparent margin, maybe the game stops rewarding opacity. If market forces can discipline a messy sector, perhaps we do not need as much regulatory machinery.

That is the seductive story. It is also incomplete.

The deeper question is not whether people want transparency. Of course they do. The harder question is this: what happens when a market becomes more legible, but the actors inside it are still free to design the rules of legibility? In health care, transparency is not the finish line. It is a new battlefield. Once prices are visible, the contest shifts from hiding margins to shaping benchmarks, from concealing spread to controlling definitions, from making money in the dark to making money through the structure of disclosure itself.

That is why the most interesting developments in insurance and drug pricing are not simply about lower prices. They are about a much more fundamental change: the movement from opaque pricing to curated pricing.

---

Visibility Is Not the Same as Simplicity

A health plan that gives nearly instant cost and coverage information seems like a straightforward upgrade. It reduces friction, helps patients anticipate bills, and makes decision making more concrete. In everyday life, we trust visible prices for groceries, flights, and most retail purchases because transparency is what lets a market feel real. A shelf tag is not just a number, it is a form of trust.

But health care is not a normal retail market. The person choosing care often is not the person paying the full bill. The payer, the employer, the pharmacy, the PBM, the manufacturer, and the patient all see different slices of the same transaction. So when a plan says, in effect, “here is your cost right now,” it solves one problem while exposing another: the price you see is only as meaningful as the rules that produced it.

Think of transparency like a map. A map can help you navigate, but only if the legend is honest, the scale is accurate, and the roads have not been redrawn by whoever profits from the traffic. In health benefits, the map itself can become a product. A system can advertise clarity while quietly choosing which landmarks to show, which routes to highlight, and which tolls to omit.

That is why visible pricing is both empowering and dangerous. It empowers because it gives people information. It is dangerous because once information becomes central, strategic actors stop merely charging fees and start engineering perceptions of fairness. The appearance of simplicity can mask a more sophisticated form of control.

---

The Real Game: From Hidden Spread to Visible Benchmarking

Prescription drug pricing makes this especially clear. Cost based pricing sounds almost commonsense, even righteous. Why should a pharmacy reimbursement formula be detached from the actual economics of dispensing a drug? Why not reimburse based on acquisition cost, plus a fair fee for the pharmacist, rather than on some mysterious spread hidden in the system?

The problem is that “cost based” is not a single model. It is a family of models, and the details matter. One benchmark might be acquisition cost plus a margin. Another might rely on a national average price. Another might fall back on wholesale pricing, or usual and customary charges, if the preferred data are unavailable. Each benchmark feels more objective than old-fashioned black box pricing, but each one also creates new incentives.

This is the crucial shift: when a system becomes benchmark driven, the benchmark becomes the prize.

Imagine a race in which the fastest runner does not matter as much as the person who gets to decide where the finish line is drawn. A cost based pharmacy network can look like a cleaner race, but only if the benchmark is insulated from manipulation. If one party can influence the acquisition price, define the cost basis, control the rebate logic, or set the dispensing fee, then “transparency” merely relocates discretion.

That is the deeper insight. The old system hid profit in spread. The new system may hide profit in the selection of the reference price. This is not a cosmetic change. It is a transfer of power from the visible invoice to the invisible methodology.

---

Vertical Integration Makes Transparency Harder, Not Easier

The most revealing tension in health pricing is that the very firms promising simplicity often sit at multiple points in the chain. The same organization can act as manufacturer, distributor, pharmacy, and benefit manager. In theory, that can eliminate waste and reduce friction. In practice, it also means one entity may influence the price at several stages and then compare its own outputs to its own inputs.

That is a peculiar kind of efficiency. It may lower administrative complexity, but it also weakens the external checks that make market pricing meaningful. If one company can help establish the benchmark, participate in the network that gets reimbursed by that benchmark, and decide how much of the fee flows to each participant, then the question is not merely whether the price is fair. The question is whether fairness can even be independently verified.

This is where the rhetoric of market discipline becomes slippery. Markets work best when parties face prices they did not write themselves. A farmer cannot meaningfully test crop yields if also writing the weather report. Likewise, a drug pricing system cannot claim clean cost discipline if the same enterprise can shape the cost, the channel, and the reimbursement formula.

Transparency without structural separation can become theater.

That does not mean vertical integration is always bad. It can reduce handoffs, improve coordination, and create genuine efficiencies. But it should make us more cautious, not less, about claims of simple cost alignment. In heavily intermediated markets, the hard question is not whether costs are visible. It is whether any one actor can own too many of the mirrors.

---

What Patients and Employers Actually Need: Not Just Price, But Proof

There is a tempting belief that the solution to complexity is more information. But in health care, people do not merely need information. They need verifiable confidence.

That distinction matters. Information tells you what the price is. Verification tells you whether the price deserves to be trusted. A patient who sees a lower copay wants more than a number on a screen. An employer who switches PBMs wants more than a promise of lower spend. Both want assurance that the savings are not just moved around, delayed, or reclassified.

This is why so many pricing reforms generate excitement and skepticism at the same time. They often improve a visible metric while leaving the underlying architecture untouched. A lower pharmacy reimbursement may help one side of the ledger while hidden administrative fees reappear elsewhere. A transparent plan may make shopping easier while the real negotiation still happens upstream in contract language and rebate flows.

The result is a familiar pattern: the system gets more readable, but not necessarily more accountable.

A useful way to think about this is the difference between a storefront and a supply chain. The storefront is where the customer experiences the price. The supply chain is where value is created, moved, transformed, and often obscured. Most health reform focuses on the storefront because that is where the pain is visible. But unless the supply chain is simplified or independently audited, visible prices may merely reflect hidden compromises upstream.

That is why employer switching can matter. When large self insured employers move between benefit managers, they are not just shopping for lower administrative fees. They are testing whether alternative architectures can create cleaner incentives. In a sense, they are asking whether a different intermediary can reduce not just cost, but the cost of not knowing.

---

A Better Mental Model: Health Pricing as an Integrity Problem

The best way to understand this landscape is not to ask, “Who offers the cheapest price?” That question is too shallow. The better question is, “Which system preserves integrity as it lowers price?”

Integrity has four parts:

1. Clear benchmarks: The reference point for pricing should be understandable and auditable.
2. Limited self dealing: The same entity should not be able to dominate multiple roles in the transaction without checks.
3. Aligned incentives: Savings should flow to the party taking the risk or paying the bill, not disappear into opaque spreads.
4. Fallback rules that are fair: When standard data are unavailable, the system should default in ways that do not reward arbitrary discretion.

This lens changes the debate. A plan is not good because it is transparent in the abstract. It is good because its transparency survives contact with incentives. A pharmacy network is not good because it talks about acquisition cost. It is good because acquisition cost cannot be gamed, the markup is visible, and the allocation of that markup is independently testable.

That is a much higher bar than “cost based pricing.” But it is the right bar, because health care is not a simple marketplace where price tags emerge naturally. It is an ecosystem of negotiated dependencies. In such systems, the goal is not merely to reveal prices. It is to make price formation legible, contestable, and trustworthy.

The real reform is not cheaper numbers. It is fewer opportunities to redefine the numbers.

---

Key Takeaways

• Do not confuse transparency with accountability. A visible price can still be engineered through opaque benchmarks, hidden fees, or self serving rules.
• Ask who controls the reference point. In cost based systems, the benchmark is often more important than the posted price.
• Watch for vertical integration. When one company spans manufacturing, pharmacy, and benefit management, it can influence both the inputs and the payout structure.
• Prefer systems that are auditable, not just understandable. A good plan lets you verify how a price was formed, not merely see the final number.
• Evaluate reforms by who captures the savings. Lower costs only matter if they reach the patient, employer, or plan sponsor rather than being absorbed upstream.

---

The Future of Pricing Will Be Decided in the Open, but Not Necessarily Fairly

The central illusion of modern health pricing is that openness automatically produces fairness. In reality, openness changes the form of the struggle. It shifts competition from hidden spreads to visible formulas, from secret markups to controlled benchmarks, from confusion to strategic clarity.

That is both promising and sobering. Promising, because the more visible the system becomes, the harder it is to justify pure opacity. Sobering, because every new transparent framework invites a new generation of sophisticated arbitrage. Once price becomes legible, the smartest players stop asking how to hide it and start asking how to shape it.

So the real question is not whether health care should become more transparent. It should. The real question is whether transparency will be built as a public good, or as a new layer of managed perception.

If we get this wrong, we will keep applauding the same old system with better lighting. If we get it right, transparency will not just show us the price. It will show us who had the power to create it in the first place.